14 November 2022

Dual inhibition of IL17A and IL17F in AxSpA

A new target for treatment in AxSpA is the dual inhibition of IL17A and IL17F (IL17A/F). IL17A is a key driver of the inflammation in the AxSpA and Psoriatic Arthritis (PsA). IL17A and its structurally related IL17F share biologic functional properties. Inhibition of both cytokines (IL17A/F) should result in a greater clinical benefit in AxSpA and PsA than IL17A inhibition alone.

RheumNowâs expanded coverage of the #ACR22 Annual meeting is sponsored in part by Bristol-Myers Squibb. All content c

Tweet Author

RheumNow

Tweet Content

RheumNow’s expanded coverage of the #ACR22 Annual meeting is sponsored in part by Bristol-Myers Squibb. All content chosen by RheumNow & its Faculty.

RT @RichardPAConway: Ozen et al. Safety Opioids vs NSAIDs in RA. Similar risks except 2-fold increase in VTE with opioid

Tweet Author

RichardPAConway

Tweet Content

Ozen et al. Safety Opioids vs NSAIDs in RA. Similar risks except 2-fold increase in VTE with opioids. @RheumNow #ACR22 Abstr#1646 https://t.co/kWBf8t4TFh https://t.co/dxKoilOhFX

Links

Major Adverse Cardiovascular Events and Mortality with Opioids versus NSAIDs In… https://acrabstracts.org/abstract/major-adverse-cardiovascular-events-and-morta…

RT @AurelieRheumo: FORWARD databank RA 4500+ opioid & 11000+ NSAID MACE 133 vs. 392 (18.2/1000 PY vs. 14.6/1000 P

Tweet Author

AurelieRheumo

Tweet Content

FORWARD databank RA 4500+ opioid & 11000+ NSAID MACE 133 vs. 392 (18.2/1000 PY vs. 14.6/1000 PY) Deaths 95 vs. 228 (12.6/1000 PY vs. 8.2/1000 PY) IR MACE & mortality NSAID < Opioids Driven by VTE > Opioids vs NSAIDs HR=2.45 https://t.co/fl7cJNGrvu Abs#1646 #ACR22 @Rheumnow https://t.co/wV5hYMfYLl

Links

Major Adverse Cardiovascular Events and Mortality with Opioids versus NSAIDs In… http://bit.ly/3Gfl9C7

RT @RichardPAConway: Brooks et al. Risk lung cancer higher in RA (aHR 1.53) and RA-ILD (aHR 3.06) than controls. Persist

Tweet Author

RichardPAConway

Tweet Content

Brooks et al. Risk lung cancer higher in RA (aHR 1.53) and RA-ILD (aHR 3.06) than controls. Persisted in non-smokers, non-RA-ILD, incident RA @RheumNow #ACR22 Abstr#1647 #ACRbest https://t.co/c18k9OLDIm https://t.co/UTgYZAmfmk

Links

Increased Risk of Lung Cancer in Rheumatoid Arthritis and Rheumatoid Arthritis-… https://acrabstracts.org/abstract/increased-risk-of-lung-cancer-in-rheumatoid-a…

RT @KDAO2011: Dr. B Humphrey #ACR22 #Osteoporosis Guidelines: Treatment algorithms for GIO and in special populations (a

Tweet Author

KDAO2011

Tweet Content

Dr. B Humphrey #ACR22 #Osteoporosis Guidelines: Treatment algorithms for GIO and in special populations (age < 18) @rheumnow https://t.co/dZ02kuOUeH

RT @RichardPAConway: Juge @Juge_P_A @PhilippeDieude et al. Increased mortality in RA-ILD. HR 3.4 vs RA. <75 HR 4.8 .

Tweet Author

RichardPAConway

Tweet Content

Juge @Juge_P_A @PhilippeDieude et al. Increased mortality in RA-ILD. HR 3.4 vs RA. <75 HR 4.8 . ILD first HR 8.4 @RheumNow #ACR22 Abstr#1959 #ACRbest https://t.co/mnbeBPuyC7 https://t.co/sLU2ZuTMw7

Links

Increased Mortality in Patients with RA-Associated Interstitial Lung Disease: D… https://acrabstracts.org/abstract/increased-mortality-in-patients-with-ra-assoc…

RT @drdavidliew: Of course, imaging itself can be useful in PMR in many situations - and, like GCA, there are merits to

Tweet Author

drdavidliew

Tweet Content

Of course, imaging itself can be useful in PMR in many situations - and, like GCA, there are merits to all of ultrasound, MRI, and PET/CT. Nice summary slide @drceowen #ACR22 @RheumNow https://t.co/1LO3DvW7tm

RT @ericdeinmd: 14M111 Updated ACR Guidelines for Glucocorticoid-Induced Osteoporosis #ACR22 ð¦´ð¦´ Special pops recs

Tweet Author

ericdeinmd

Tweet Content

14M111 Updated ACR Guidelines for Glucocorticoid-Induced Osteoporosis #ACR22 🦴🦴 Special pops recs for: Organ transplant - against romosozumab (CVD risk) Women of child bearing age (not planning) - BIS/TERI Children - Vit D/Ca unless Fx Very high doses: more aggressive @RheumNow https://t.co/xY7Yc3BANj

RT @JulianSegan: Paul Emery presenting phase 2 data Peresolimab in RA. Novel mechanism aiming to restore immune homeosta

Tweet Author

JulianSegan

Tweet Content

Paul Emery presenting phase 2 data Peresolimab in RA. Novel mechanism aiming to restore immune homeostasis. Exciting for rheumatic disease beyond RA. @RheumNow #ACR22 #LateBreaking https://t.co/oOjvo5YmDB

Topics

RheumNowâs expanded coverage of the #ACR22 Annual meeting is sponsored in part by Bristol-Myers Squibb. All content c

RT @RichardPAConway: Ozen et al. Safety Opioids vs NSAIDs in RA. Similar risks except 2-fold increase in VTE with opioid

RT @AurelieRheumo: FORWARD databank RA 4500+ opioid & 11000+ NSAID MACE 133 vs. 392 (18.2/1000 PY vs. 14.6/1000 P

RT @RichardPAConway: Brooks et al. Risk lung cancer higher in RA (aHR 1.53) and RA-ILD (aHR 3.06) than controls. Persist

RT @KDAO2011: Dr. B Humphrey #ACR22 #Osteoporosis Guidelines: Treatment algorithms for GIO and in special populations (a

RT @RichardPAConway: Juge @Juge_P_A @PhilippeDieude et al. Increased mortality in RA-ILD. HR 3.4 vs RA. <75 HR 4.8 .

RT @drdavidliew: Of course, imaging itself can be useful in PMR in many situations - and, like GCA, there are merits to

RT @ericdeinmd: 14M111 Updated ACR Guidelines for Glucocorticoid-Induced Osteoporosis #ACR22 ð¦´ð¦´ Special pops recs

RT @JulianSegan: Paul Emery presenting phase 2 data Peresolimab in RA. Novel mechanism aiming to restore immune homeosta

Do you get our email newsletter?

RheumNowâs expanded coverage of the #ACR22 Annual meeting is sponsored in part by Bristol-Myers Squibb. All content c

RT @RichardPAConway: Ozen et al. Safety Opioids vs NSAIDs in RA. Similar risks except 2-fold increase in VTE with opioid

RT @AurelieRheumo: FORWARD databank RA 4500+ opioid &amp; 11000+ NSAID MACE 133 vs. 392 (18.2/1000 PY vs. 14.6/1000 P

RT @RichardPAConway: Brooks et al. Risk lung cancer higher in RA (aHR 1.53) and RA-ILD (aHR 3.06) than controls. Persist

RT @KDAO2011: Dr. B Humphrey #ACR22 #Osteoporosis Guidelines: Treatment algorithms for GIO and in special populations (a

RT @RichardPAConway: Juge @Juge_P_A @PhilippeDieude et al. Increased mortality in RA-ILD. HR 3.4 vs RA. &lt;75 HR 4.8 .

RT @drdavidliew: Of course, imaging itself can be useful in PMR in many situations - and, like GCA, there are merits to

RT @ericdeinmd: 14M111 Updated ACR Guidelines for Glucocorticoid-Induced Osteoporosis #ACR22 ð¦´ð¦´ Special pops recs

RT @JulianSegan: Paul Emery presenting phase 2 data Peresolimab in RA. Novel mechanism aiming to restore immune homeosta

RheumNowâs expanded coverage of the #ACR22 Annual meeting is sponsored in part by Bristol-Myers Squibb. All content c

RT @AurelieRheumo: FORWARD databank RA 4500+ opioid & 11000+ NSAID MACE 133 vs. 392 (18.2/1000 PY vs. 14.6/1000 P

RT @RichardPAConway: Juge @Juge_P_A @PhilippeDieude et al. Increased mortality in RA-ILD. HR 3.4 vs RA. <75 HR 4.8 .

RT @ericdeinmd: 14M111 Updated ACR Guidelines for Glucocorticoid-Induced Osteoporosis #ACR22 ð¦´ð¦´ Special pops recs